This is a routine executive departure with no financial guidance or operational changes. Monitor for any future 8-K regarding a replacement for the Executive Chair role, but no immediate trading action is warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $27.07entry
- T+1 · 3mo ago +2.22%α +2.25% · $27.67
- T+5 · 3mo ago −5.43%α −5.83% · $25.60
- T+20 · 2mo ago −16.81%α −16.41% · $22.52
- T+60 · 15d ago −16.99%α −14.86% · $22.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics disclosed the end of Dr. Barbara Weber's employment as Executive Chair, effective August 3, 2026, with her resignation from all officer and board positions. The departure is not due to any disagreement with the company, and a separation agreement with standard severance benefits has been offered. This is a routine executive transition with no financial impact disclosed, making it a neutral event for the stock.
Key Facts
- Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026.
- Dr. Weber resigned from all officer and board member positions, including the board of directors.
- The resignation was not a result of any disagreement with the company.
- The company offered severance pay through December 31, 2026, COBRA reimbursement, and accelerated vesting of certain equity awards.
- CEO Malte Peters remains in place; no other executive changes were announced.
Financial Impact
Severance pay at current base salary through Dec 31, 2026, plus COBRA reimbursement and accelerated vesting of 12 months of equity awards, amounts not disclosed.
Risk Factors
- Potential leadership vacuum if a new Executive Chair is not named promptly.
- Minor overhang from accelerated equity vesting, though amounts are undisclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-338480 |
| Document: 0001193125-26-338480-index-headers.html | 0001193125-26-338480 |
| Document: 0001193125-26-338480-index.html | 0001193125-26-338480 |
| Document: 0001193125-26-338480.txt | 0001193125-26-338480 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers